GlycoMimetics (NASDAQ:GLYC) plans to test GMI-1359, a dual function antagonist, in breast cancer patients whose tumors have spread to bone.
GMI-1359 targets both E-selectin and CXCR4, which are involved in tumor trafficking and metastasis. The trial will assess GMI-1359’s dose escalation, safety and pharmacodynamics.
“If ultimately shown safe and effective in clinical trials, this agent could represent a potentially novel approach to treating metastatic cancer, and we’re pleased to begin exploring the use of this investigational therapy in individuals with metastatic cancer,” Dr. Kelly Marcom, a co-principal investigator of the planned study, said in a statement.
GlycoMimetics expects to initiate this trial in the second half of 2019.
